License: Creative Commons Attribution 4.0 PDF - Published Version (4MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-587511
- DOI to cite this document:
- 10.5283/epub.58751
Abstract
Our previously reported HDAC6 inhibitor (HDAC6i) Marbostat-100 (4) has provided many arguments for further clinical evaluation. By the substitution of the acidic hydrogen of 4 for different carbon residues, we were able to generate an all-carbon stereocenter, which significantly improves the hydrolytic stability of the inhibitor. Further asymmetric synthesis has shown that the (S)-configured ...
Owner only: item control page